Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
Hermine I BrunnerNicolino RupertoZbigniew ZuberRubén CutticaVladimir KeltsevRicardo M XavierRuben Burgos-VargasInmaculada Calvo PenadesEarl D SilvermanGraciela EspadaManuel Ferrandiz ZavalerYukiko KimuraCarolina DuarteChantal Job-DeslandreRik JoosWendy DouglassSunethra WimalasunderaKamal N BharuchaChris WellsDaniel J LovellAlberto MartiniFabrizio de Benedettinull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
Patients treated with TCZ for polyarticular-course JIA showed high-level disease control for up to 2 years. The TCZ safety profile was consistent with that previously reported.